British Journal of Clinical Pharmacology · 2013 · 112 citations · 61 references
PharmacyPharmacokineticsPharmacologyDrug ClearanceHepatic PharmacokineticsPharmacokinetic ModelingCytochrome P450 InteractionsDrug DispositionHepatic Drug MetabolismModel EvaluationPregnancy PharmacologyReproductive PharmacologyCyp2c19 Drug MetabolismGestational PharmacokineticsMaternal Drug DispositionPregnancy Drug ClearancePregnancy Pharmacokinetic ModelingPregnancy-induced Pharmacokinetic ChangesPregnancy-related Pharmacokinetic ChangesPregnancy-related Pharmacokinetics
AIM: Conducting PK studies in pregnant women is challenging. Therefore, we asked if a physiologically-based pharmacokinetic (PBPK) model could be used to predict the disposition in pregnant women of drugs cleared by multiple CYP enzymes. METHODS: We expanded and verified our previously published pregnancy PBPK model by incorporating hepatic CYP2B6 induction (based on in vitro data), CYP2C9 induction (based on phenytoin PK) and CYP2C19 suppression (based on proguanil PK), into the model. This model accounted for gestational age-dependent changes in maternal physiology and hepatic CYP3A, CYP1A2 and CYP2D6 activity. For verification, the pregnancy-related changes in the disposition of methadone (cleared by CYP2B6, 3A and 2C19) and glyburide (cleared by CYP3A, 2C9 and 2C19) were predicted. RESULTS: Predicted mean post-partum to second trimester (PP : T2 ) ratios of methadone AUC, Cmax and Cmin were 1.9, 1.7 and 2.0, vs. observed values 2.0, 2.0 and 2.6, respectively. Predicted mean post-partum to third trimester (PP : T3 ) ratios of methadone AUC, Cmax and Cmin were 2.1, 2.0 and 2.4, vs. observed values 1.7, 1.7 and 1.8, respectively. Predicted PP : T3 ratios of glyburide AUC, Cmax and Cmin were 2.6, 2.2 and 7.0 vs. observed values 2.1, 2.2 and 3.2, respectively. CONCLUSIONS: Our PBPK model integrating prior physiological knowledge, in vitro and in vivo data, allowed successful prediction of methadone and glyburide disposition during pregnancy. We propose this expanded PBPK model can be used to evaluate different dosing scenarios, during pregnancy, of drugs cleared by single or multiple CYP enzymes.
61
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Masaru Hirano, Kazuya Maeda, Yoshihisa Shitara et al. · Drug Metabolism and Disposition · 2006 · 301 citations
Medicine, Biochemistry, Pharmacology +15